KMID : 0620920230550102248
|
|
Experimental & Molecular Medicine 2023 Volume.55 No. 10 p.2248 ~ p.2259
|
|
Vascular regeneration and skeletal muscle repair induced by long-term exposure to SDF-1¥á derived from engineered mesenchymal stem cells after hindlimb ischemia
|
|
Kim Jin-Ju
Park Jae-Hyun Kim Hyeok Sim Woo-Sup Hong Seok-Beom Choi Yeon-Jik Kim Hyo-Jin Kim Yu-Ra Kim Dong-Ha Kang Sun-Woong Ban Ki-Won Park Hun-Jun
|
|
Abstract
|
|
|
Despite recent progress in medical and endovascular therapy, the prognosis for patients with critical limb ischemia (CLI) remains poor. In response, various stem cells and growth factors have been assessed for use in therapeutic neovascularization and limb salvage in CLI patients. However, the clinical outcomes of cell-based therapeutic angiogenesis have not provided the promised benefits, reinforcing the need for novel cell-based therapeutic angiogenic strategies to cure untreatable CLI. In the present study, we investigated genetically engineered mesenchymal stem cells (MSCs) derived from human bone marrow that continuously secrete stromal-derived factor-1¥á (SDF1¥á-eMSCs) and demonstrated that intramuscular injection of SDF1¥á-eMSCs can provide long-term paracrine effects in limb ischemia and effectively contribute to vascular regeneration as well as skeletal muscle repair through increased phosphorylation of ERK and Akt within the SDF1¥á/CXCR4 axis. These results provide compelling evidence that genetically engineered MSCs with SDF-1¥á can be an effective strategy for successful limb salvage in limb ischemia.
|
|
KEYWORD
|
|
Peripheral vascular disease, Regeneration
|
|
FullTexts / Linksout information
|
|
|
|
Listed journal information
|
|
|